Chordia Therapeutics Inc. (190A) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 686.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.27
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: JP
• Employees: 22
• Sector: Healthcare
• Sector Strength: 50
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -6.12
• Shares Outstanding: 68,988,800
• 10 Day Avg. Volume: 413,870
• 30 Day Avg. Volume: 686,693
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: ―

Chordia Therapeutics Inc. faces significant financial and operational challenges, primarily due to revenue losses and profitability issues. The strong balance sheet with no debt is a positive aspect but overshadowed by ongoing cash flow difficulties. Technical indicators suggest a bearish trend, and valuation metrics are unfavorable with negative earnings. These factors collectively result in a lower stock score, emphasizing the need for strategic improvements to enhance financial stability and market performance.

Chordia Therapeutics Inc. Business Overview & Revenue Model

Company Description

Chordia is focused on the oncology area, with its target areas ranging from exploratory research to Proof of Concept (POC). For subsequent business development, we will build a system that allows us to make the best choices for maximizing corporate value, such as out-licensing and joint development and sales.

How the Company Makes Money

Chordia Therapeutics Inc. primarily generates revenue through the development and commercialization of its proprietary drug candidates. The company earns income from licensing agreements, milestone payments, and royalties from partnerships with larger pharmaceutical companies. These collaborations often involve co-development or marketing arrangements that help Chordia Therapeutics bring its therapies to market. Additionally, the company may receive funding through grants, research collaborations, and potential government or non-governmental support aimed at fostering innovation in cancer treatment.

Chordia Therapeutics Inc. Financial Statement Overview

Summary

Chordia Therapeutics Inc. demonstrates significant financial challenges, with no revenue in the latest period and negative profitability margins. While the balance sheet is strong with no debt and high equity, cash flow issues persist, raising concerns about future financial stability. The company needs to address revenue generation and cost management to improve its financial health.

Income Statement

Chordia Therapeutics Inc. has faced significant revenue volatility, with revenues dropping to zero in 2024 after a peak in 2023. The company reported negative gross profit margins and net profit margins due to an absence of revenue and high operational expenses. The EBIT and EBITDA margins are also negative, indicating profitability challenges.

Balance Sheet

The company maintains a strong equity position with no debt, resulting in a debt-to-equity ratio of zero. However, the return on equity is negative due to persistent net losses. The equity ratio remains high, reflecting a solid capital structure despite operational losses.

Cash Flow

Chordia Therapeutics Inc. shows negative free cash flow growth, with cash outflows exceeding cash inflows. The operating cash flow to net income ratio is negative, highlighting cash flow challenges. Despite negative free cash flow, the company manages a strong cash position from financing activities.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	0.00	2.50B	0.00	800.00M
Gross Profit	-4.09M	2.50B	-3.15M	800.00M
EBITDA	-1.82B	218.10M	-1.77B	-687.06M
Net Income	-1.83B	223.34M	-1.78B	-527.11M
Balance Sheet
Total Assets	4.63B	4.91B	4.50B	2.27B
Cash, Cash Equivalents and Short-Term Investments	4.33B	4.80B	4.25B	2.00B
Total Debt	0.00	0.00	0.00	0.00
Total Liabilities	471.07M	408.24M	221.41M	214.95M
Stockholders Equity	4.16B	4.50B	4.28B	2.06B
Cash Flow
Free Cash Flow	-1.94B	543.01M	-1.72B	-546.92M
Operating Cash Flow	-1.94B	543.73M	-1.70B	-544.59M
Investing Cash Flow	-10.96M	345.00K	-14.70M	-2.36M
Financing Cash Flow	1.48B	0.00	3.98B	1.53B

Chordia Therapeutics Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 179.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:190A, the sentiment is Negative. The current price of 179 is below the 20-day moving average (MA) of 184.15, below the 50-day MA of 200.54, and below the 200-day MA of 240.14, indicating a bearish trend. The MACD of -5.04 indicates Negative momentum. The RSI at 39.07 is Neutral, neither overbought nor oversold. The STOCH value of 30.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:190A.

Chordia Therapeutics Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4350	71 Outperform	¥14.55B	12.04		2.51%	5.93%	-36.11%
2796	62 Neutral	¥5.87B	―		2.79%	16.60%	-19.16%
8095	60 Neutral	¥20.70B	8.67		3.52%	12.75%	-191.21%
4890	58 Neutral	¥9.62B	53.89		―	101.17%	―
Sector *	50 Neutral	AU$2.46B	3.13	10.94%	2.67%	36.93%	13.84%
190A	45 Neutral		―		―	―	―
NHCZF	―	$769.65M	63.88	3.89%	―	―	―

Chordia Therapeutics Inc. Corporate Events

Chordia Therapeutics Regains Rights to CTX-177 as Ono Discontinues Development

Chordia Therapeutics Inc. has announced that Ono Pharmaceutical Co., Ltd. will discontinue the development of CTX-177 (ONO-7018) for strategic reasons, returning all rights to Chordia. While this decision ends the potential for milestone payments from Ono, Chordia does not foresee an immediate impact on its current R&D activities, including ongoing studies of its lead pipeline asset, rogocekib. The company will explore future business options for CTX-177 and manage the transition of ongoing studies and data.

Chordia Therapeutics Reports Financial Losses for Six-Month Period Ending February 2025

Chordia Therapeutics Inc. reported its non-consolidated financial results for the six months ending February 28, 2025, showing a net loss with operating and ordinary profits also in the negative. The company’s total assets and equity ratio have decreased compared to the previous period, indicating financial challenges. Despite these losses, there are no changes in accounting policies or dividend forecasts, and the company maintains a stable number of shares outstanding.